Haemonetics Corporation Reports Strong Financial Performance in Second Quarter of Fiscal 2027

Haemonetics Corporation Reports Strong Financial Performance in Q2 Fiscal 2027

Haemonetics Corporation (NYSE: HAE), a prominent global medical technology firm, recently released its financial outcomes for the second quarter of fiscal year 2027, which concluded on September 26, 2026. This announcement was made public on November 5, 2026, and can be viewed on the company's Investor Relations website.

Overview

In a robust statement regarding its financial performance, Haemonetics indicated that it would also engage in a conference call and webcast aimed at investors and analysts. This call will provide further insights into the company’s results and allow for a Q&A session to address inquiries from stakeholders. The conference is set to commence at 8:00 AM ET on the same day as the announcement.

Conference Call and Webcast Details

Individuals wishing to participate in the conference call can register directly on the Haemonetics website. Upon registration, they will receive specific dial-in information and a personal PIN. Although it isn’t mandatory, attendees are encouraged to join approximately 10 minutes before the event starts to ensure a prompt beginning. The live webcast can also be accessed on the Investor Relations segment of the Haemonetics website. For those who cannot attend the live session, a replay will be available starting at 11:00 AM ET on the same day, remaining accessible for one year via the provided webcast link.

Earnings Materials

In addition to the earnings release, Haemonetics has also uploaded supplementary materials which will be referenced during the conference call. This includes the Second Quarter Fiscal 2027 Earnings Release and the corresponding Supplemental Earnings Presentation.

About Haemonetics

Haemonetics Corporation is dedicated to advancing medical technology with a focus on enhancing healthcare quality and operational efficiency. The company's product offerings are categorized into several business segments including Apheresis, MedSurg, and Interventional Technologies.
1. Apheresis Business: This segment features unique technologies aimed at improving safety, donor satisfaction, and operational efficiency for blood and plasma collectors worldwide.
2. MedSurg Business: Haemonetics provides Blood Management Technologies to aid clinical decision-making and optimize blood product management.
3. Interventional Technologies: This includes innovative vascular closure systems and sensor-guided technologies that are designed to improve procedural effectiveness and enhance patient experiences.

In summary, Haemonetics is continuously striving to support healthcare advancements through innovative solutions. For a more detailed exploration of their products and corporate vision, interested parties can visit www.haemonetics.com.

For further inquiries related to investor relations, Olga Guyette, the Vice President of Investor Relations, can be contacted at 781-356-9763. Alternatively, David Trenk, Senior Manager of Investor Relations, is also available at 203-733-4987. Any media-related questions can be directed to Josh Gitelson at 781-356-9776.